Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mmmm, I get it. You are color blind. Than explains it all
Currently $1.02 up $0.085 or 9.09%.
When is up is green
When is down is red
So, for your understanding please switch the colors whenever you se them so you won't confuse the rest of us normal people
And, what about "you will no see $1 again?"
Chumppunk,
Right on !!!.
How did you know ?.
Render to Caesar the things that are Caesar's; and to God the things that are God's.
Black-ops,
You forgot to comment that when they impart their infinite wisdom on us, poor uninformed, they should tell us in what side of their flipping cycle they are in (long, short) so we can interpret their very sophisticated interpretation of the SP properly.
Otherwise we will be completely lost in the wild without a wordy guide.
djjazzyjeff,
But his word is not EVIDENCE.
Hey Donald,
HOW IS THAT PRO140 WORKING FOR YA
FDA decides the science not investors.
Amatuer,
BTD - he said he delivered some new data to FDA only 6 days back, as per FDA process, the 60 day clock will start again.
“tour de force” meeting !!
My notes from an extraordinary meeting. We are going ahead (in spite of naysayers and shorts). Maybe I am missing a lot, but these are my mean takeaways:
BLA clinical has been finalized!!! (remember we have rolling application and this is the one that takes more time to study by FDA).
There will not be any dilutive financing. S0 we can rest easy with this one.
Financing is coming. Several possibilities (4 investors under evaluation). Most likely will be benign debt.
Coronavirus: one hour ago IND and protocol have been completed. Expected to file FDA tomorrow. Announcement on Monday with all details. Quest clinical in San Francisco ready to inject first patient New York Presbiterian Brooklyn Methodist want to enroll patients Stefano Rusconi Italy wan to enroll patients also.
Going full blast with Nash
Up-Listing a priority, however the cash in hand requirements ($100M NSE, $90M NASDAQ) are such that is better to wait until financing or deals are made.
Will present in conference American Association of cancer research
Commercial name: Virologics
Question about GILD: “GILD: I am hoping we don’t get an offer until we get a BTD designation. If somebody offers something and shareholders approve I am up for it.”
Dr. Patterson in Coronavirus: Of the 20 companies listed in article most are working on Vaccine or anti-viral. Only one (us) is ready with a good safety profile.
IND and protocol for MS in a couple of weeks.
March 29 meeting: Oncologist Pathologists, radiologists, open discussion and great opportunity to share ideas and come up with strategies.
BTD for MTNBC applied on January 10th updated data on Feb 6th. According to FDA guidelines 60 Days Will be up on 6 days or so unless they choose to reset the date.
New BTD we have IND, Lazeai have received. Have 2 patinet with different cancers and another one we could file based in mechanism of action. Lab doctor called several times and say that he had never seen such results so definitely there are responders.
TFDA for Cancer, HIV and Coronavirus” Already signed letter of intent an NDA 30 days started already. AMAREX was the venue. They shared data with their branch in Taiwan so it will be expedited for BTD for cancer and for HIV. They want to see some paints from that region.
CFDA document already transferred. They already transmitted them to CFDA so is in progress.
Longen: 9 days from today Letter of Intent will lapse. Working hard on final term sheet. Will inform what happens and if it happens.
Licensing with another very solid company with financial background (Taiwan) will be announcing something shorty. Both companies want to buy 24K plus 600K vials of commercial grade Leronlimab for Coronavirus and Oncology. Might get to the point that we are short of vials.
Update in patients:
7 Injected Yesterday 3/4/2020
8 Will be Injected Friday 3/6/2020
9 Passed screening, injection date TBD
10 Passed screening, injection date TBD
11 Will be Phase1/2b in Houston site
12 Will be Phase 1/2b in Houston site
Even BLA or FDA approval won’t justify this market cap
Just great !!
Making some money …
Up 3% and much more to come.
Thanks for asking
Plus they are from GA my state not from Canada ;)
If they had real news, they would have scheduled it for Monday or Tuesday AM, not hung it out a week away. Gives us a week of hope before the usual mediocre updates.
Whatever …
Expecting news on patient #5. They are worth BILLIONS (for those that can understand what is at stake).
Have you shorted yet ??? Please help yourselves.
And good luck !!!!
DrugDoctor,
Did you read the papers ?? Any comments on the facts (either you being a "Doctor" or not ?).
If this is your answer to several papers and Science …
Well, to put in some way: who are you trying to fool ???
Definitely not me.
Absolutely !!!. Count me in.
Black-ops,
That is why I am not posting here any more any substancial information/opinion.
And I paid more than $100 dollars for a year subscription !!!
Big mistake.
Basically this board cannot be a good forum for ideas for a simple reason: some are deleted if they do not agree with some people's opinions.
Is like a country without free press. The result: a place when one learns nothing.
Thankfully there are other more balanced and useful opinion forums.
Good luck to you all and I hope you can read this before it gets deleted.
The product they have we don’t know what kind of revenue will have
They have vyera as partner and vyera have only 7 million in revenue and have some legal issues as well
The risk to cydy investors here is it likely will take an additional 3 to 4 years IF the fda approves this before it even has a chance to reach the market..... that’s extremely time consuming and very costly.
Huge gamble imho. Especially considering biotech / pharmaceuticals is a risky investment in itself.
The average time from FDA application to approval of drugs is 12 years, and the estimated average cost of taking a new drug from concept to market exceeds $1 billion.
Jurisdiction of agency's government: United States
CYDY has now advanced into irrelevance mode.
LongPenny,
Excellent work you are doing.
We don't need liars out there spewing their poison to fit their interests.
They know the science is solid, so revert to personal attacks.
Low, very low.
Amatuer,
Well, if you think like that the solution is extremelly simple: buy all you can of Merck, forget about CYDY.
Good luck !!!
Me, I will continue with CYDY. Why ??? Better R/R, better prospects, much better drug.
But, heck, we are in a free country. So, good luck with K !!!
Thanks Ohm !!!
Very useful, will study the papers.
Ohm, Vision and Value,
Fair enough. The different CoVs genus receptor-binding domains bind to different receptors and since the SARS epidemic, the crystal structures of ?ve coronavirus S1 domains complexed with their respective receptor have been determined: angiotensin-converting enzyme ACE , aminopeptidase N APN , dipeptidyl peptidase 4 DPP4 , carboxypeptidase.
Three of the four known protein receptors for coronaviruses are peptidases: ACE2, APN and DPP4. It is highly unlikely that the use of peptidases as coronavirus receptors is simply a coincidence. They are all recognized by S1-CTDs (C terminal domains) of different coronaviruses. so, all of them have some similarity.
However, for, the new (Wuhan) coronavirus it was found that these 4 new insertions are unique to 2019-nCoV and are not present in other coronaviruses analyzed. Another group from China had documented three insertions comparing fewer spike glycoprotein sequences of coronaviruses.
Unexpectedly, all the insertions got aligned with Human immunodeficiency Virus-1 (HIV-1). Further analysis revealed that aligned sequences of HIV-1 with 2019-nCoV were derived from surface glycoprotein gp120 and from Gag protein (366-384 amino acid) (Table 1). Gag protein of HIV is involved in host membrane binding, packaging of the virus and for the formation of virus-like particles.
Gp120 plays crucial role in recognizing the host cell by binding to the primary receptor CD4.This binding induces structural rearrangements in GP120, creating a high affinity binding site for a chemokine co-receptor like CXCR4 and/or CCR5.
Most of the above is cut-and-paste from recent papers.
My point here is that we don't know anything about this NEW coronavirus that already has shown different characteristics from the other 8 strains (and three genus) already identified. As this one has 4 insertions that rearranges gp120 making it more "binding" to CCR5.
If this is the case, I was submitting that Leronlimab might be of use.
I don't pretend to know that this is the case. Just proposing an "educated opinion" based of the scant literature available yet on the subject.
Vision and Value:
As we all know this is a very recent development and, therefore, there is not much information to go about.
I came across a very interesting paper published by Delhi's Kusuma School of biological sciences, IIT. They used computational tools to analyze the sequence and structural features of 2019-nCoV
https://www.biorxiv.org/content/10.1101/2020.01.30.927871v1.full.pdf
Their conclusions are very interesting, below a summary that concerns us (emphasis are mine):
1) The amino acid sequence presents 4 insertions (an insertion is a modification in the “normal” amino genomic sequence) of that are not present in other coronaviruses analyzed
2) Surprisingly, each of the four inserts aligned with short segments of the Human immunodeficiency Virus-1 (HIV-1) proteins
3) The first 3 inserts aligned to short segments of amino acid residues in HIV-1 gp120 (glycoprotein GP120 is a glycoprotein exposed on the surface of the HIV envelope), the insert 4 aligned to HIV-1 Gag (with gaps). Gag , or group specific antigen, is the major structural protein of HIV-1 and all other retroviruses and comprises about 50% of the mass of a viral particle.
4) It is unlikely that all 4 inserts in the 2019-nCoV spike glycoprotein fortuitously match with 2 key structural proteins of an unrelated virus (HIV-1).
5) The novel inserts are part of the receptor binding site of 2019-nCoV
And they mention that:
Gag protein of HIV is involved in host membrane binding, packaging of the virus and for the formation of virus-like particles. Gp120 plays crucial role in recognizing the host cell by binding to the primary receptor CD4 (CD4 receptor binding is the most obvious step in HIV infection). This binding induces structural rearrangements in GP120, creating a high affinity binding site for a chemokine co-receptor like CXCR4 and/or CCR5.
Ohm,
Excellent post, very enlightening.
With the occupancy test arguably CDY could try to experiment by trying to blockade completely the CCR5 receptors for some time and mesure the virologic load re-appearance.
It could possibly be that a "full coverage" of CCR5 (by reasonable overload since it is safe) for some time can eliminate the virus completely, not being able to recruit more CD4+ cells.
This is a Super-Duper article.
One of the best I have read in many years !!!
More than a year ago I was commenting on the irrational "blindness" of GILD to evaluate and B.O. CYDY.
It was a perfect fit. Hell, as mentioned in the article, IT IS A PERFCT MATCH; However, for reason that go beyond my understanding they decided to take a pass.
HUGE MISTAKE
The article is factual, accurate and drives home the point. GILD will be in DEEP trouble if it keeps on kicking its lunch-box.
And the point is ???
Nader rightfully opposed the R/S (the right decision showing how good CEO he is) and that was it.
Again, what is your point ??
It just seems fishy on the timing of the PR.
Amatuer,
Reverse Split is or should be coming
Ohm,
You hit the nail on the head.
Leronlimab just partially inhibits the CCR5 receptor and still allows an immune response.
Yes,
And we will make some money while you watch us ….
A secret, but, please, don't tell anybody: " It will go much higher than $2"
Please don't tell anybody.
OK ???
Whatever you do, don't sell before the up listing effect has been fully digested by the SP.
It will have a large influence for few months.
Then, re-ascertain and sell if you think price is stable.
I personally won't touch a share until the full Oncology portafolio has been completely implemented.
Or we have been BO, of course.
Saltz,
IMO BTD is biggest SP mover over the next couple months.
Branster,
Patients #3 and #4 are CRITICAL.
If they confirm, we are sitting in a blockbuster. If the price does not move is because there are many of us fully invested (can't but more) and many more that don't know that we exist, or, not smart enough to understand the magnitude of what these results mean.
Name a drug that can stop metastasis.
Metastasis kills more than 90% of cancer sufferers.
Get the point??
Rhetoric question as I know you know.
Vision and Value,
Thanks, Below a copy-and-paste from an artice, witch says, I believe, what you are pointing out.
Thus, monocytes and CCR5+ T cells upregulate PDL-1 in response to IFN-a, and IFN-a is partially responsible for AT-2 HIV-induced PDL-1.
Branster,
Absolutely right.
I roughly discounted 50% of our net sales part. This would include the royalties. I believe these are 10.5% in total (Progenics, AbbVie, CGS).
Maybe numbers will need some adjustment, supposed to be "napkin" computations
In any case, we are grossly undervalued as the majority of non-revenue Biotech's are valuated in base of POTENTIAL.
We have lots of the latter.
JA2626,
Oh man, sorry to hear you blocked him/her.
We need some humor here and the buffoon was making me laugh. Or maybe the Doctor is taking too many of his drugs ??
Please reconsider.
Vision and Value,
Interesting discussion.
As you know, during HIV-1 infection PD-1 and PDL-1 expression increase.
An study suggests that monocites and CCR5+ T cells of HIV-uninfected donors upregulated PDL-1.
It follows that a CCR5 antagonist will reduce the number of active CCR5+ cells effectively reducing PDL-1 expression.
In the same article it was mentioned that IFN-a-receptor subunit 2 (IFNAR2), was expressed only by CCR5+ T cells and monocytes, explaining why these leukocytes responded to HIV-induced IFN-a.
From : PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes
I have the PDF document but you can find the paper in several sites. If needed let me know and I will forward via email.